Market Closed -
BME
11:35:26 2024-04-26 am EDT
5-day change
1st Jan Change
28.96
EUR
+0.49%
+10.37%
-29.50%
Presentation Operator MessageOperator (Operator)Welcome to Pharma Mar's First Quarter 2023 Res...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 23
CI
Transcript : Pharma Mar, S.A., 2023 Earnings Call, Feb 29, 2024
Feb. 29
Pharma Mar, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 27
CI
Pharma Mar's Sylentis Meets Primary Endpoint for Dry Eye Disease Medication
Dec. 18
MT
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong
Dec. 12
MT
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao
Dec. 04
MT
Pharma Mar's Partner Wins Commercialization Approval for Zepzelca in Peru
Nov. 07
MT
PharmaMar Gets $10 Million Milestone Payment from Janssen Under Yondelis Licensing Deal
Nov. 06
MT
Transcript : Pharma Mar, S.A., Q3 2023 Earnings Call, Oct 27, 2023
23-10-27
Pharma Mar, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-25
CI
Pharma Mar, S.A. commences an Equity Buyback Plan, under the authorization approved on May 31, 2023.
23-09-05
CI
Transcript : Pharma Mar, S.A., H1 2023 Earnings Call, Jul 28, 2023
23-07-28
Pharma Mar, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023
23-07-27
CI
PharmaMar Secures Taiwan Regulatory Approval for Lung Cancer Treatment
23-07-11
MT
Monetary optimism and Inditex drive the Ibex-35 to one-and-a-half month highs
23-06-07
RE
The Ibex rises cautiously as it waits for central banks to make their moves
23-06-06
RE
Pharma Mar Recruits First Patient for Solid Tumor Treatment Trial
23-05-04
MT
Transcript : Pharma Mar, S.A., Q1 2023 Earnings Call, Apr 27, 2023
23-04-27
Ibex-35 gives ground as it digests results, awaiting central banks
23-04-27
RE
Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-25
CI
Transcript : Pharma Mar, S.A., 2022 Earnings Call, Mar 01, 2023
23-03-01
Pharma Mar, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022
23-02-27
CI
Pharma Mar Wins Conditional Approval For Lung Cancer Drug In Israel
23-01-31
MT
Spain's Pharma Mar Wins Approval for Lung Cancer Drug in Mexico
23-01-24
MT
Spain's Pharma Mar Kicks Off First-in-Human Study of Investigational Tumor Treatment
22-12-30
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Companyâs product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
More about the company
Last Close Price
28.96
EUR
Average target price
49.2
EUR
Spread / Average Target
+69.89%
Consensus
1st Jan change
Capi.
-29.50% 545M -4.66% 86.13B +1.32% 39.82B -19.27% 30.42B +57.86% 25.23B -16.09% 15.35B -9.14% 11.95B -17.69% 11.6B -43.00% 11.51B +5.24% 8.71B
Biopharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1